TrialSignal transduction and targeted therapy2026

Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial.

Shichun Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.